Balancing benefit and risk of medicines: a systematic review and classification of available methodologies
- 13 May 2014
- journal article
- review article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 23 (7) , 667-678
Abstract
Background: The need for formal and structured approaches for benefit–risk assessment of medicines is increasing, as is the complexity of the scientific questions addressed before making decisions on the benefit–risk balance of medicines. We systematically collected, appraised and classified available benefit–risk methodologies to facilitate and inform their future use.Methods: A systematic review of publications identified benefit–risk assessment methodologies. Methodologies were appraised on their fundamental principles, features, graphical representations, assessability and accessibility. We created a taxonomy of methodologies to facilitate understanding and choice.Results: We identified 49 methodologies, critically appraised and classified them into four categories: frameworks, metrics, estimation techniques and utility survey techniques. Eight frameworks describe qualitative steps in benefit–risk assessment and eight quantify benefit–risk balance. Nine metric indices include threshold indices to measure either benefit or risk; health indices measure quality‐of‐life over time; and trade‐off indices integrate benefits and risks. Six estimation techniques support benefit–risk modelling and evidence synthesis. Four utility survey techniques elicit robust value preferences from relevant stakeholders to the benefit–risk decisions.Conclusions: Methodologies to help benefit–risk assessments of medicines are diverse and each is associated with different limitations and strengths. There is not a ‘one‐size‐fits‐all’ method, and a combination of methods may be needed for each benefit–risk assessment. The taxonomy introduced herein may guide choice of adequate methodologies. Finally, we recommend 13 of 49 methodologies for further appraisal for use in the real‐life benefit–risk assessment of medicines. Copyright © 2014 John Wiley & Sons, Ltd.Keywords
Funding Information
- Innovative Medicines Initiative Joint Undertaking (115004)
- European Union's Seventh Framework Programme (FP7/2007-2013)
- EFPIA
This publication has 93 references indexed in Scilit:
- A framework for organizing and selecting quantitative approaches for benefit-harm assessmentBMC Medical Research Methodology, 2012
- The Use of Clinical Utility Assessments in Early Clinical DevelopmentThe AAPS Journal, 2009
- Are Adult Patients More Tolerant of Treatment Risks Than Parents of Juvenile Patients?Risk Analysis, 2008
- Net Efficacy Adjusted for Risk (NEAR): A Simple Procedure for Measuring Risk:Benefit BalancePLOS ONE, 2008
- Quantitative risk-benefit analysis of natalizumabNeurology, 2008
- Combination of direct and indirect evidence in mixed treatment comparisonsStatistics in Medicine, 2004
- Benefit-Risk AnalysisDrug Safety, 2003
- Concepts in Risk-Benefit Assessment A Simple Merit Analysis of a Medicine?Drug Safety, 1996
- Comparing Treatments Using Quality-Adjusted Survival: The Q-TWiST MethodThe American Statistician, 1995
- A new proposal for benefit-less-risk analysis in clinical trialsControlled Clinical Trials, 1994